{"id":"cggv:09113d8c-ba63-40f1-9c8f-08b67c6c867cv2.0","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:09113d8c-ba63-40f1-9c8f-08b67c6c867c_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10023","date":"2024-09-03T16:33:05.716Z","role":"Publisher"},{"id":"cggv:09113d8c-ba63-40f1-9c8f-08b67c6c867c_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10023","date":"2024-09-03T17:00:00.000Z","role":"Approver"}],"curationReasons":[{"id":"cg:RecurationTiming"},{"id":"cg:DiseaseNameUpdate"},{"id":"cg:ErrorClarification"}],"evidence":[{"id":"cggv:09113d8c-ba63-40f1-9c8f-08b67c6c867c_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:09113d8c-ba63-40f1-9c8f-08b67c6c867c_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:4ae5d05f-95cd-402b-a46d-535504edc8d1","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:7414866a-4707-40b6-9c28-9021ed89341f","type":"FunctionalAlteration","dc:description":"Decreased homology-directed repair (HDR) by a number of missense variants and sensitivity to ionizing radiation and cispaltin.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/30925164","type":"dc:BibliographicResource","dc:abstract":"The BARD1 protein, which heterodimerizes with BRCA1, is encoded by a known breast cancer susceptibility gene. While several BARD1 variants have been identified as pathogenic, many more missense variants exist that do not occur frequently enough to assign a clinical risk. In this paper, whole exome sequencing of over 10,000 cancer samples from 33 cancer types identified from somatic mutations and loss of heterozygosity in tumors 76 potentially cancer-associated BARD1 missense and truncation variants. These variants were tested in a functional assay for homology-directed repair (HDR), as HDR deficiencies have been shown to correlate with clinical pathogenicity for BRCA1 variants. From these 76 variants, 4 in the ankyrin repeat domain and 5 in the BRCT domain were found to be non-functional in HDR. Two known benign variants were found to be functional in HDR, and three known pathogenic variants were non-functional, supporting the notion that the HDR assay can be used to predict the clinical risk of BARD1 variants. The identification of HDR-deficient variants in the ankyrin repeat domain indicates there are DNA repair functions associated with this domain that have not been closely examined. In order to examine whether BARD1-associated loss of HDR function results in DNA damage sensitivity, cells expressing non-functional BARD1 variants were treated with ionizing radiation or cisplatin. These cells were found to be more sensitive to DNA damage, and variations in the residual HDR function of non-functional variants did not correlate with variations in sensitivity. These findings improve the understanding of BARD1 functional domains in DNA repair and support that this functional assay is useful for predicting the cancer association of BARD1 variants.","dc:creator":"Adamovich AI","dc:date":"2019","dc:title":"Functional analysis of BARD1 missense variants in homology-directed repair and damage sensitivity."},"rdfs:label":"Adomvich HDR"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0.5},{"id":"cggv:09113d8c-ba63-40f1-9c8f-08b67c6c867c_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:d854a1c6-fe36-4b13-97fe-70e4158d3fc5","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:438967c0-f289-4f4e-b5e6-29e91c779377","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"Conditional deletion of BARD1 in mammary tissue induced mammary carcinoma that are indistinguishable from BRCA1 mice, which have been reported as  resembling basal-like breast tumors of human BRCA1 mutation carriers. Tumours showed features similar to human breast carcinoma, specifically histopathology similar to, TP53 expression similar to and chromosomal instability similar to human breast carcinoma. ","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/18443292","type":"dc:BibliographicResource","dc:abstract":"Women with germ-line mutations of the BRCA1 tumor suppressor gene are highly susceptible to breast and ovarian cancer. The protein product of BRCA1 is involved in a broad spectrum of biological processes and interacts with many diverse proteins. One of these, BARD1, associates with BRCA1 to form a heterodimeric complex that is enzymatically active as an ubiquitin E3 ligase. Although the BRCA1/BARD1 heterodimer has been implicated in several aspects of BRCA1 function, its role in tumor suppression has not been evaluated. To address this question, we generated mouse strains carrying conditional alleles of either Bard1 or Brca1 and used Cre recombination to inactivate these genes in mammary epithelial cells. Significantly, the conditional Bard1- and Brca1-mutant mice developed breast carcinomas that are indistinguishable from each other (and from those of double conditional Bard1/Brca1-mutant animals) with respect to their frequency, latency, histopathology, and cytogenetic features. Reminiscent of the basal-like breast carcinomas seen in human BRCA1 mutation carriers, these tumors are \"triple negative\" for estrogen and progesterone receptor expression and HER2/neu amplification. They also express basal cytokeratins CK5 and CK14, have an elevated frequency of p53 lesions, and display high levels of chromosomal instability. The remarkable similarities between the mammary carcinomas of Bard1-, Brca1-, and Bard1/Brca1-mutant mice indicate that the tumor suppressor activities of both genes are mediated through the BRCA1/BARD1 heterodimer.","dc:creator":"Shakya R","dc:date":"2008","dc:title":"The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression."},"rdfs:label":"BARD1 CKO - mammary"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1,"dc:description":"Decreasing the score to allocate 2 points across two similar models, both are LOF variants resulting in breast cancer similar to human phenotype."},{"id":"cggv:56d4a0d3-752b-4b54-bbe1-9b14dc98abf2","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:07796aed-42c2-49c5-b736-c334b291d035","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"MCF7 derived tumor mass within the local mammary gland and were marked by prominent nucleoli with scant cytoplasm and high proliferation. Tumour had cells with genomic instability, ","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/33623049","type":"dc:BibliographicResource","dc:abstract":"To date, a large number of mutations have been screened from breast and ovarian cancer patients. However, most of them are classified into benign or unidentified alterations due to their undetectable phenotypes. Whether and how they could cause tumors remains unknown, and this significantly limits diagnosis and therapy. Here, in a study of a family with hereditary breast and ovarian cancer, we find that two BARD1 mutations, P24S and R378S, simultaneously exist in cis in surviving cancer patients. Neither of the single mutations causes a functional change, but together they synergetically impair the DNA damage response and lead to tumors in vitro and in vivo. Thus, our report not only demonstrates that BARD1 defects account for tumorigenesis but also uncovers the potential risk of synergetic effects between the large number of cis mutations in individual genes in the human genome.","dc:creator":"Li W","dc:date":"2021","dc:title":"A synergetic effect of BARD1 mutations on tumorigenesis."},"rdfs:label":"li "}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1,"dc:description":"Changed score to allocate 2 points across 2 non-human model systems, PMID 18443292 also reports a mouse model with LOF BARD1 variant resulting in a breast cancer like phenotype."}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":2.5},{"id":"cggv:09113d8c-ba63-40f1-9c8f-08b67c6c867c_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:09113d8c-ba63-40f1-9c8f-08b67c6c867c_cc_el","type":"EvidenceLine","evidence":[{"id":"cggv:99fa4ed4-80db-4479-b239-b3da0c3a3669","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:99fa4ed4-80db-4479-b239-b3da0c3a3669_cc_evidence_item","type":"Finding","caseCohort":{"id":"cggv:28292ff7-4a46-45d6-b6fb-fd982c5e4783","type":"Cohort","allGenotypedSequenced":2134,"alleleFrequency":0.003280224929709466,"detectionMethod":"26 known or proposed breast cancer susceptibility genes","evidence":[{"id":"cggv:99fa4ed4-80db-4479-b239-b3da0c3a3669_cc_evidence_item"}],"numWithVariant":7,"relatedCondition":{"id":"obo:MONDO_0016419"}},"controlCohort":{"id":"cggv:f650df74-cf52-4499-9378-c501f2f42eb3","type":"Cohort","allGenotypedSequenced":26375,"alleleFrequency":0.001251184834123223,"evidence":[{"id":"cggv:99fa4ed4-80db-4479-b239-b3da0c3a3669_cc_evidence_item"}],"numWithVariant":33},"lowerConfidenceLimit":1.34,"method":{"id":"cg:AggregateVariantAnalysis"},"pValue":0.0122,"statisticalSignificanceType":"","statisticalSignificanceValue":3.18,"statisticalSignificanceValueType":"Odds Ratio","upperConfidenceLimit":7.36,"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/28649662","type":"dc:BibliographicResource","dc:abstract":"Understanding the gene-specific risks for development of breast cancer will lead to improved clinical care for those carrying germline mutations in cancer predisposition genes. We sought to detail the spectrum of mutations and refine risk estimates for known and proposed breast cancer susceptibility genes. Targeted massively-parallel sequencing was performed to identify mutations and copy number variants in 26 known or proposed breast cancer susceptibility genes in 2134 ","dc:creator":"Slavin TP","dc:date":"2017","dc:title":"The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk."},"rdfs:label":"slavin"}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria","strengthScore":4},{"id":"cggv:e54cca9a-ded8-4ac7-814f-cd5a08815a50","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:e54cca9a-ded8-4ac7-814f-cd5a08815a50_cc_evidence_item","type":"Finding","caseCohort":{"id":"cggv:da254578-c875-4982-93e8-12dec59dd639","type":"Cohort","allGenotypedSequenced":28536,"alleleFrequency":0.001822259601906364,"detectionMethod":"16panl genes were assessed. BRCA1 and BRCA2 variant containing sampels not included in the analysis","evidence":[{"id":"cggv:e54cca9a-ded8-4ac7-814f-cd5a08815a50_cc_evidence_item"}],"numWithVariant":52,"relatedCondition":{"id":"obo:MONDO_0007254"}},"controlCohort":{"id":"cggv:c8501107-8485-4aef-ac08-b876a10d72be","type":"Cohort","allGenotypedSequenced":26193,"alleleFrequency":0.0005726720879624327,"evidence":[{"id":"cggv:e54cca9a-ded8-4ac7-814f-cd5a08815a50_cc_evidence_item"}],"numWithVariant":15},"lowerConfidenceLimit":1.31,"method":{"id":"cg:AggregateVariantAnalysis"},"pValue":0.002261,"statisticalSignificanceType":"","statisticalSignificanceValue":2.16,"statisticalSignificanceValueType":"Odds Ratio","upperConfidenceLimit":3.63,"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/28418444","type":"dc:BibliographicResource","dc:abstract":"Germline pathogenic variants in BRCA1 and BRCA2 predispose to an increased lifetime risk of breast cancer. However, the relevance of germline variants in other genes from multigene hereditary cancer testing panels is not well defined.","dc:creator":"Couch FJ","dc:date":"2017","dc:title":"Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer."},"rdfs:label":"couch-ambry"}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria","strengthScore":4},{"id":"cggv:836d7795-96e0-4cb0-83cf-25a26ef4a093","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:836d7795-96e0-4cb0-83cf-25a26ef4a093_cc_evidence_item","type":"Finding","caseCohort":{"id":"cggv:f263219a-7f86-4dcb-b042-8612288d40bb","type":"Cohort","allGenotypedSequenced":4469,"alleleFrequency":0.005146565227120161,"detectionMethod":"ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, RAD51C, RAD51D, and TP53 also tested","evidence":[{"id":"cggv:836d7795-96e0-4cb0-83cf-25a26ef4a093_cc_evidence_item"}],"numWithVariant":23,"relatedCondition":{"id":"obo:MONDO_0016419"}},"controlCohort":{"id":"cggv:c334c696-f2ef-4082-bc14-12abdf29e35c","type":"Cohort","allGenotypedSequenced":37265,"alleleFrequency":0.000966053938011539,"evidence":[{"id":"cggv:836d7795-96e0-4cb0-83cf-25a26ef4a093_cc_evidence_item"}],"numWithVariant":36},"lowerConfidenceLimit":3.17,"method":{"id":"cg:AggregateVariantAnalysis"},"pValue":0.000010,"statisticalSignificanceType":"","statisticalSignificanceValue":5.35,"statisticalSignificanceValueType":"Odds Ratio","upperConfidenceLimit":9.04,"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/31036035","type":"dc:BibliographicResource","dc:abstract":"The role of the BARD1 gene in breast cancer (BC) and ovarian cancer (OC) predisposition remains elusive, as published case-control investigations have revealed controversial results. We aimed to assess the role of deleterious BARD1 germline variants in BC/OC predisposition in a sample of 4920 BRCA1/2-negative female BC/OC index patients of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC).","dc:creator":"Weber-Lassalle N","dc:date":"2019","dc:title":"Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer."},"rdfs:label":"GC-HBOC"}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria","strengthScore":4},{"id":"cggv:01c43d5d-1d48-4301-b7a0-f861c290996f","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:01c43d5d-1d48-4301-b7a0-f861c290996f_cc_evidence_item","type":"Finding","caseCohort":{"id":"cggv:21b69f18-9c61-4128-886b-c7a8e9da22b1","type":"Cohort","allGenotypedSequenced":126,"alleleFrequency":0.05555555555555555,"detectionMethod":"PCR based purification of exons and exon/intron boundaries of BARD1 only, followed by sequencing ","evidence":[{"id":"cggv:01c43d5d-1d48-4301-b7a0-f861c290996f_cc_evidence_item"}],"numWithVariant":7,"relatedCondition":{"id":"obo:MONDO_0016419"}},"controlCohort":{"id":"cggv:fb53daa0-c2f2-439d-b638-c2d23f4f380a","type":"Cohort","allGenotypedSequenced":1018,"alleleFrequency":0.0137524557956778,"detectionMethod":"Controls were tested for he Cys557Ser variant only","evidence":[{"id":"cggv:01c43d5d-1d48-4301-b7a0-f861c290996f_cc_evidence_item"}],"numWithVariant":14},"lowerConfidenceLimit":107,"method":{"id":"cg:SingleVariantAnalysis"},"pValue":0.005,"statisticalSignificanceType":"","statisticalSignificanceValue":4.2,"statisticalSignificanceValueType":"Odds Ratio","upperConfidenceLimit":10.7,"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/15342711","type":"dc:BibliographicResource","dc:creator":"Karppinen SM","dc:date":"2004","dc:title":"Mutation screening of the BARD1 gene: evidence for involvement of the Cys557Ser allele in hereditary susceptibility to breast cancer."},"rdfs:label":"karpinnen"}],"specifiedBy":"GeneValidityCaseControlSingleVariantAnalysisCriteria","strengthScore":4},{"id":"cggv:e4c9f1b5-020f-4ac6-95fd-4dfb1af31f13","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:e4c9f1b5-020f-4ac6-95fd-4dfb1af31f13_cc_evidence_item","type":"Finding","caseCohort":{"id":"cggv:e7c386ce-aee4-4ebc-9274-6f04e9408246","type":"Cohort","allGenotypedSequenced":53461,"alleleFrequency":0.001159723910888311,"detectionMethod":"34 genes analysed","evidence":[{"id":"cggv:e4c9f1b5-020f-4ac6-95fd-4dfb1af31f13_cc_evidence_item"}],"numWithVariant":62,"relatedCondition":{"id":"obo:MONDO_0007254"}},"controlCohort":{"id":"cggv:a481d348-f8a6-4ef4-8486-357e721f2811","type":"Cohort","allGenotypedSequenced":60466,"alleleFrequency":0.0005292230344325737,"detectionMethod":"34 genes analysed","evidence":[{"id":"cggv:e4c9f1b5-020f-4ac6-95fd-4dfb1af31f13_cc_evidence_item"}],"numWithVariant":32},"lowerConfidenceLimit":1.35,"method":{"id":"cg:AggregateVariantAnalysis"},"pValue":0.00098,"statisticalSignificanceType":"","statisticalSignificanceValue":2.09,"statisticalSignificanceValueType":"Odds Ratio","upperConfidenceLimit":3.23,"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/33471991","type":"dc:BibliographicResource","dc:abstract":"Genetic testing for breast cancer susceptibility is widely used, but for many genes, evidence of an association with breast cancer is weak, underlying risk estimates are imprecise, and reliable subtype-specific risk estimates are lacking.","dc:creator":"Breast Cancer Association Consortium","dc:date":"2021","dc:title":"Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women."},"rdfs:label":"BCAC Dorling"}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria","strengthScore":4,"dc:description":"This is a large case-control study shows a significant association with moderate odds ratio (OR) 2.09 (1.35â€“3.23) of aggregated pathogenic BARD1 variants with overall breast cancer and an increased association in ER negative OR 5.99 (3.51-10.21) and triple negative breast cancer OR 9.29 (4.58-18.85) (4 points)."},{"id":"cggv:11a3abb9-ca18-4426-8ef1-2515e22574ad","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:11a3abb9-ca18-4426-8ef1-2515e22574ad_cc_evidence_item","type":"Finding","caseCohort":{"id":"cggv:e563712b-b919-4de6-827d-fd8c0584075c","type":"Cohort","allGenotypedSequenced":26384,"alleleFrequency":0.002463614311704063,"evidence":[{"id":"cggv:11a3abb9-ca18-4426-8ef1-2515e22574ad_cc_evidence_item"}],"numWithVariant":65,"relatedCondition":{"id":"obo:MONDO_0016419"}},"controlCohort":{"id":"cggv:b0fb65de-db54-413f-a66c-69a7f53514cd","type":"Cohort","allGenotypedSequenced":64649,"alleleFrequency":0.001299324042135222,"evidence":[{"id":"cggv:11a3abb9-ca18-4426-8ef1-2515e22574ad_cc_evidence_item"}],"numWithVariant":84},"lowerConfidenceLimit":1.35,"method":{"id":"cg:AggregateVariantAnalysis"},"pValue":0.0019,"statisticalSignificanceType":"","statisticalSignificanceValue":2.39,"statisticalSignificanceValueType":"Odds Ratio","upperConfidenceLimit":4.4,"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/35172496","type":"dc:BibliographicResource","dc:abstract":"Multiple-gene, next-generation sequencing panels are increasingly used to assess hereditary cancer risks of patients with diverse personal and family cancer histories. The magnitude of breast and ovarian cancer risk associated with many clinically tested genes, and independent of family cancer history, remains to be quantified.","dc:creator":"Kurian AW","dc:date":"2017","dc:title":"Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women."},"rdfs:label":"Kurian"}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria","strengthScore":4},{"id":"cggv:6facb512-93f6-47a9-b138-51acdd1d1186","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:6facb512-93f6-47a9-b138-51acdd1d1186_cc_evidence_item","type":"Finding","caseCohort":{"id":"cggv:ed002b1a-2d71-49c2-868d-997e21db3e90","type":"Cohort","allGenotypedSequenced":778,"alleleFrequency":0.0102827763496144,"detectionMethod":"Germline DNA from an independent neuroblastoma cohort  was sequenced using Illumina custom capture panels, including a germline panel newly designed\nfor this study (166 genes see Supplementary Table 2).","evidence":[{"id":"cggv:6facb512-93f6-47a9-b138-51acdd1d1186_cc_evidence_item"}],"numWithVariant":8,"relatedCondition":{"id":"obo:MONDO_0005072"}},"controlCohort":{"id":"cggv:985a1122-d9a6-406e-97d0-9037d81672a2","type":"Cohort","allGenotypedSequenced":6293,"alleleFrequency":0.0003178134435086604,"detectionMethod":"Cancer-free control data were obtained from the Penn Medicine BioBank (PMBB; n=6295) and the Genome Aggregation Database (gnomAD v2.1) without cancer (n=15 708).","evidence":[{"id":"cggv:6facb512-93f6-47a9-b138-51acdd1d1186_cc_evidence_item"}],"numWithVariant":2},"lowerConfidenceLimit":6.4352,"method":{"id":"cg:AggregateVariantAnalysis"},"pValue":8.0E-7,"statisticalSignificanceType":"","statisticalSignificanceValue":32.3,"statisticalSignificanceValueType":"Odds Ratio","upperConfidenceLimit":310.3526,"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/37688579","type":"dc:BibliographicResource","dc:abstract":"Neuroblastoma is an embryonal cancer of the developing sympathetic nervous system. The genetic contribution of rare pathogenic or likely pathogenic germline variants in patients without a family history remains unclear.","dc:creator":"Kim J","dc:date":"2024","dc:title":"Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survival."},"rdfs:label":"Kim_NB_2024"}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria","strengthScore":3,"dc:description":"Enrichment of P-LP variants in CPGs in neuroblastoma vs. gnomAD 2.1: Cases (8/778), Controls (15/15693), OR=10.7535, p-value=0.0000066, 95%CI=3.9361-27.1293."}],"specifiedBy":"GeneValidityOverallCaseControlEvidenceCriteria","strengthScore":12}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":8935,"specifiedBy":"GeneValidityCriteria10","strengthScore":14.5,"subject":{"id":"cggv:c03d1c57-cbca-46a2-ac02-3fb3c921fc27","type":"GeneValidityProposition","disease":"obo:MONDO_0700267","gene":"hgnc:952","modeOfInheritance":"obo:HP_0000006"},"version":"2.0","dc:description":"BARD1 was discovered as a binding partner to BRCA1 in 1996 (Wu et al., PMID: 8944023) and was first reported in relation to hereditary breast cancer in 1998 (Thai et al., PMID: 9425226). BARD1-related cancer predisposition is characterized by a susceptibility to breast cancer with emerging evidence suggesting the association of other cancer types including neuroblastoma. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found no difference in molecular mechanism(s) or inheritance pattern. Therefore, breast cancer and neuroblastoma have been lumped into this curation. Please note, autosomal dominant familial ovarian cancer (MONDO:0016248) has been curated separately due to conflicting evidence. The mechanism of pathogenicity is loss of function in which BRCA1 binding is disrupted and subsequent loss of DNA damage response. 6 predicted null variants (nonsense and frameshift) and 2 missense variants reported in 8 probands with breast cancer in 5 publications (PMIDs: 2550351, 31371347, 21344236, 23334666, 28726808) are included in this curation. Several case-control studies further support the association of breast cancer (PMIDs: 15342711, 28418444, 28649662, 31036035, 33471991, 35172496). Additionally, a case-control study supports the association of neuroblastoma (PMIDs: 37688579, 37688570, 36747619). More evidence is available in the literature, but the maximum score for genetic evidence (12 Points) has been reached. This gene-disease relationship is also supported by experimental evidence, including in vitro functional assays and animal models (2.5 Points, PMIDs: 18443292, 30925164, 33623049). Cells models with BARD1 variants showed impaired DNA damage in line with the proposed mechanism. In addition, both mammary gland conditional knockout Bard1 mice and a BARD1 variant xenograft model showed development of a breast cancer-like mammary tumor. In summary, there is definitive evidence supporting the relationship between BARD1 and autosomal dominant inherited BARD1-related cancer predisposition. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This gene-disease pair was originally evaluated as definitive for hereditary breast cancer (MONDO:0016419) by the Breast/Ovarian Cancer GCEP on 08/09/2017. This re-curation as definitive was approved by the ClinGen Hereditary Cancer GCEP on 01/26/2024 (SOP Version 10).","dc:isVersionOf":{"id":"cggv:09113d8c-ba63-40f1-9c8f-08b67c6c867c"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}